arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

ACADIA PHARMACEUTICALS INC

ACAD
$29.23 ▲ +0.78 (+2.72%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
67 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
74
Health
Good
Bullish
auto_awesome

Analytical Summary

ACADIA PHARMACEUTICALS INC shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $5.0B
Dividend Yield
Revenue Growth 9.7%
Op. Margin -1.7%
ROIC -0.3%
FCF / Share $0.17
Trailing P/E 1461.5x
Price / Book 4.0x
FCF Yield 0.6%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$268.06M
↑ +9.7%
Net Income Profit after all expenses
$3.64M
↓ -80.8%
Operating Margin Operating profit as % of sales
-1.7%
↓ -128.1% 56th
FCF / Share Free cash flow per share
$0.17
↑ +38.5%
trending_up

Bullish Indicators

  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
71
Returns
93
Cash Quality
31

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters